Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
August 02, 2017 16:05 ET
|
Actinium Pharmaceuticals
Actinium raised total gross proceeds of $16.125 million NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...
Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
July 28, 2017 09:10 ET
|
Actinium Pharmaceuticals
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock
July 27, 2017 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET
July 13, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Webinar topics will cover FDA Advisory Panel on Mylotarg, developments with other CD33 targeted therapies and update on Actimab-A - Webinar to be led by Dr. Joseph Jurcic, Director of Hematologic...
Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET
July 06, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Webinar topics will cover FDA Advisory Panel on Mylotarg, developments with other CD33 targeted therapies and update on Actimab-A - Webinar to be led by Dr. Joseph Jurcic, Director of Hematologic...
Genoptix and Bionano Genomics Announce Strategic Alliance
June 28, 2017 08:00 ET
|
BioNano Genomics; Genoptix, Inc.
SAN DIEGO and CARLSBAD, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- Genoptix, Inc., a leading oncology diagnostics and informatics company, and Bionano Genomics®, Inc., a company focused on genome...
Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming Quarters
June 15, 2017 08:30 ET
|
Actinium Pharmaceuticals
- Iomab-B Phase 3 SIERRA trial enrollment is accelerating as the number of clinical trial sites increase, competitive position as only induction and conditioning regimen remains unchallenged -...
Actinium Pharmaceuticals Announces Appointment of Nitya Ray, Ph.D. as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain and Other Key Hires in its Product Development and Manufacturing Teams
June 15, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Dr. Nitya Ray joins Actinium Executive Team with 30 years of radiopharmaceutical and biologics product development, manufacturing and strategic planning experience - Also announced is the recent...
Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
June 12, 2017 07:00 ET
|
Actinium Pharmaceuticals
Dr. Rajneesh Nath, a Principal Investigator and Director of the Bone Marrow Transplant and Acute Leukemia Program at Banner MD Anderson Cancer Center will discuss his perspectives on Iomab-B in...
Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer
June 09, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Mr. Seth to serve as Chief Executive Officer and Chairman of the Board of Directors - Independent Director Dr. Ajit Shetty appointed to the Company’s Corporate Governance, Audit and Compensation...